PURPOSE: To evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: In this Phase I dose-escalation clinical trial, 25 patients were treated in five dose tiers up to 44 Gy, administered in 5 fractions over a 2-week course. Response was assessed according to the Response Evaluation Criteria in Solid Tumors and [(18)F]-fluorodeoxyglucose standardized uptake value change on positron emission tomography-computed tomography (PET-CT). RESULTS: No Grade 3/4 or dose-limiting toxicities occurred. Four patients had Grade 1/2 acute toxicities. Four objective responses were observed, for a response rate of 17% (95% confidence interval 2%-33%). The maximum duration of response was 4 months. Twelve patients had stable disease. Median time to disease progression was 4 months, and median overall survival was 6 months. Self-reported quality of life was not significantly affected by treatment. Fluorodeoxyglucose PET was a more sensitive early-measure response to treatment than CT volume changes. CONCLUSION: Reirradiation up to 44 Gy using SBRT is well tolerated in the acute setting and warrants further evaluation in combination with conventional and targeted therapies.
PURPOSE: To evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: In this Phase I dose-escalation clinical trial, 25 patients were treated in five dose tiers up to 44 Gy, administered in 5 fractions over a 2-week course. Response was assessed according to the Response Evaluation Criteria in Solid Tumors and [(18)F]-fluorodeoxyglucose standardized uptake value change on positron emission tomography-computed tomography (PET-CT). RESULTS: No Grade 3/4 or dose-limiting toxicities occurred. Four patients had Grade 1/2 acute toxicities. Four objective responses were observed, for a response rate of 17% (95% confidence interval 2%-33%). The maximum duration of response was 4 months. Twelve patients had stable disease. Median time to disease progression was 4 months, and median overall survival was 6 months. Self-reported quality of life was not significantly affected by treatment. Fluorodeoxyglucose PET was a more sensitive early-measure response to treatment than CT volume changes. CONCLUSION: Reirradiation up to 44 Gy using SBRT is well tolerated in the acute setting and warrants further evaluation in combination with conventional and targeted therapies.
Authors: Victor H F Lee; Dora L W Kwong; To-Wai Leung; Sherry C Y Ng; Ka-On Lam; Chi-Chung Tong; Chun-Kin Sze Journal: Eur Arch Otorhinolaryngol Date: 2016-10-13 Impact factor: 2.503
Authors: Stanley I Gutiontov; Zachary S Zumsteg; Benjamin H Lok; Sean Berry; Chiaojung J Tsai; Sean M McBride; Nadeem Riaz; Oren Cahlon; Nancy Y Lee Journal: Int J Part Ther Date: 2017-03-14
Authors: Luluel Khan; Michael Tjong; Hamid Raziee; Justin Lee; Darby Erler; Lee Chin; Ian Poon Journal: Support Care Cancer Date: 2014-10-09 Impact factor: 3.603
Authors: Jean-Claude M Rwigema; Dwight E Heron; Robert L Ferris; Regiane S Andrade; Michael K Gibson; Yong Yang; Cihat Ozhasoglu; Athanassios E Argiris; Jennifer R Grandis; Steven A Burton Journal: Am J Clin Oncol Date: 2011-08 Impact factor: 2.339
Authors: Kara S Davis; John A Vargo; Robert L Ferris; Steven A Burton; James P Ohr; David A Clump; Dwight E Heron Journal: Oral Oncol Date: 2014-08-28 Impact factor: 5.337